Natalizumab-associated progressive multifocal leukoencephalopathy (PML) in multiple sclerosis (MS): “a case report from Ireland with review of literature, clinical pitfalls and future direction”

• Main Authors: Salman Mansoor, Gerard Mullane, Mohammad Hijaz Adenan, Siobhan Kelly, Aine Water, Grainne McPartland, Kevin Murphy
• Format: Article
• Language: English
• Published: SpringerOpen 2021-01-01
• Series: The Egyptian Journal of Neurology, Psychiatry and Neurosurgery
• Subjects: Natalizumab; Progressive multifocal leukoencephalopathy; Cidofovir; Mirtazapine; Steroids; Multiple sclerosis
• Online Access: https://doi.org/10.1186/s41983-020-00260-6

Abstract Background Progressive multifocal leukoencephalopathy (PML) is one of the most serious treatment-related complications that is encountered in patients with multiple sclerosis (MS). PML is a serious complication of MS treatment which is most commonly related to natalizumab. Case presentation We report clinical course of progressive multifocal leukoencephalopathy (PML) in a 40-year-old man who was on treatment for highly active relapsing-remitting multiple sclerosis with natalizumab (Nz). He was treated with steroids, cidofovir, and mirtazapine and went on to develop long-term disability. The case describes the evolution of PML from diagnosis up till 5 months with changes on sequential brain scans and clinical symptoms in our patient. Conclusion Patients who are on natalizumab should be aware and consented for the risk of PML. They should be periodically re-assessed for their relative PML risk. There is a growing body of evidence that suggests switching patients from natalizumab who have a higher risk of PML to other safer treatment options.